Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates

Group 1 - Relay Therapeutics reported a quarterly loss of $0.41 per share, better than the Zacks Consensus Estimate of a loss of $0.49, and an improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of +16.33% [1] - The company achieved revenues of $0.68 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 35.40%, compared to zero revenues a year ago [2] - Relay Therapeutics shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Relay Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.45 on $0.5 million in revenues, and -$1.86 on $19.09 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]